TickerFacts.

BridgeBio Oncology Therapeutics, Inc. (BBOT): R&D Expense

Annual figures by period end, from SEC filings.

$121.20M
Year ended 2025-12-31
$162.15M
Trailing 12 months to 2026-06-30
2024-12-31: $73.11M2025-12-31: $121.20M$121.20M
2024-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$121.20M+65.8%2026-03-05, From 2025-01-01
2024-12-31$73.11Mn/a2026-03-05, From 2024-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
BridgeBio Oncology Therapeutics, Inc. (BBOT)2025-12-31$121.20M+65.8%
Biohaven Ltd. (BHVN)2025-12-31$635.07M-20.2%
BGM Group Ltd. (BGM)2025-09-30$672.7K-50.6%
Arcutis Biotherapeutics, Inc. (ARQT)2025-12-31$77.05M+0.8%
Bicara Therapeutics Inc. (BCAX)2024-12-31$63.60M+107.8%
MoonLake Immunotherapeutics (MLTX)2025-12-31$202.86M+79.9%
Enliven Therapeutics, Inc. (ELVN)2025-12-31$85.86M+6.3%
MapLight Therapeutics, Inc. (MPLT)2025-12-31$138.35M+101.9%
Rhythm Pharmaceuticals, Inc. (RYTM)2025-12-31$167.34M-29.7%

Compare BBOT, BHVN, BGM, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗